RxDoctor Payments Data

Mrinalini Sarkar, MD

Nephrology · West Hollywood, CANPI 1932362514

Payments from drug & device makers

$310,350in general payments, 2019–2025

Across 146 payments — averaging $2125.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$156K
  • Sanofi US Services Inc.$56K
  • Amgen$52K
  • Travere Therapeutics, Inc.$21K
  • Bayer$11K
  • Baxter Healthcare$8K
  • plus $6K from 8 others

What the payments were for

  • Consulting fees$26,55130%
  • Speaking & faculty fees$47,66355%
  • Travel & lodging$8,0709%
  • Food & beverage$4,9446%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,350 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$96,594
Medicare patients
294
Services billed
776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate29$31,897
JardianceEmpagliflozin21$26,902
ClinolipidFat Emulsion/Olive/Soy/Phospho52$16,507
Sevelamer Carbonate17$4,274
RetacritEpoetin Alfa-Epbx19$3,038
Nifedipine ErNifedipine55$2,250
Tacrolimus18$2,003
Calcium Acetate15$1,028
Prednisone83$695
Bumetanide22$542
Clonidine Hcl28$513
Tamsulosin Hcl46$496
Calcitriol15$492
Carvedilol25$401
Pantoprazole Sodium26$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$156,052$31,89729 claims
Boehringer IngelheimJardiance$280$26,90221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →